Nls pharmaceutics announces $20 million standby equity distribution agreement and $2.5 million equity investment

Stans, switzerland / accesswire / september 28, 2021 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has entered into a standby equity distribution agreement, or seda, with ya ii pn, ltd.
NLSP Ratings Summary
NLSP Quant Ranking